Wode K et al., 2024-05-31: MISTRAL, a double-blind placebo-controlled trial in 290 randomised Swedish patients with advanced pancreatic cancer (143 mistletoe, 147 placebo): adding mistletoe extract to standard care did not improve overall survival (HR 1.13) or global quality of life.
No statistically significant benefit of adding ME to standard treatment was seen with respect to either OS or global health/ QoL. The adjusted hazard ratio for OS was 1.13 [0.89; 1.44], with a median survival time of 7.8 and 8.3 months for ME and placebo, respectively.
Abstract, Results
Wode K et al., 2024-05-31: MISTRAL, a double-blind placebo-controlled trial in 290 randomised Swedish patients with advanced pancreatic cancer (143 mistletoe, 147 placebo): adding mistletoe extract to standard care did not improve overall survival (HR 1.13) or global quality of life. Study type: randomized trial.
